For example, circ‐SMARCA5 can target miR‐767‐5p to inhibit the progression of multiple myeloma, and hsa_circ_0002483 can target miR‐182‐5p to inhibit the progression of non‐small‐cell lung cancer (Li et al., 2019; McCaw et al., 2019). Here, SMARCA5 is linked to plasma cell myeloma.